Eight National Key Disciplines
Department of Cardiology

Department of Cardioangiology is well-structured with all the necessary subjects. It has gradually gained its superior position in China in such subjects as cardioangiologic immunology, molecular cardiology, and targeted therapy of cardiovascular disease, cardiac electrophysiology, interventional cardiology, and echocardiography. It has made breakthroughs in the basic research of endogenous protective mechanism of cardio-cerebral blood vessels, and holds the lead in the diagnosis and treatment of aorta disease, and the application of gene diagnosis and typing.

Discipline Characteristics
1.We have inherited Tongji spirits, and taken academic standards as the essence of the department. Our diagnosis and treatment of cardiovascular diseases is in the domestic and international leading level. We provide medical services for patients in Hubei and surrounded provinces with excellent medical ethics
2.We take “clarification” as the goal, which seeks to clarify the diagnosis, make the patients understand, and treat following the principle of evidence-based medicine.
3.We especially focus on the difficult cases and mainly provide services for acute and critically ill patients. For those patients, we timely arrange discipline or hospital-wide consultation.
4.We can routinely carry out interventional screening and treatment for cardiovascular diseases skillfully, including coronary angiography and stent implantation, balloon mitral valvuloplasty, percutaneous occlusion therapy for congenital heart diseases, stent implantation for treatment of aortic dissection, pacemaker implantation and catheter ablation.
5.For etiological diagnosis and therapy of hypertension, we have performed standardized treatment and established new diagnosis techniques, which helps to provide most suitable and effective therapies for a considerable number of patients with hypertension.
6.We attach great importance to basic research in cardiovascular diseases. Such as, the mechanisms of protective endogenous molecules in cardiovascular system, risk factors and population genetics in cardiovascular diseases, and gene therapy research, etc., which are in advanced domestic level and internationally recognized.

Research fields

1.Prevention and interventional therapy for coronary heart disease and macrovascular diseases. We firstly introduced thrombolytic therapy for acute myocardial infarction. We are domestically leading in interventional therapies such as PTCA and percutaneous balloon mitral valvuloplasty. Besides, we have established the green channel and 24-hour duty system for emergency PCI for acute myocardial infarction treatment. Our research in restenosis after PCI for coronary heart disease is at the domestic leading level. Furthermore, we can perform interventional therapy for aortic dissection and aneurysm at any time in acute, subacute, or chronic period. Moreover, we can creatively perform hybrid surgery for some complicated aortic dissection patients (i.e. physicians together with surgeons performing the surgery for treatment), and simultaneously finish aortic stent implantation and PCI for patients with aortic dissection complicated with myocardial infarction. Therefore, our department turns into a national center for treatment of aortic dissection.

2.Cardiac electrophysiology. It includes basic research in cardiac electrophysiology, radiofrequency catheter ablation for supraventricular tachycardia, ventricular tachycardia, atrial flutter and pacemaker implantation. Our success rate and safety in atrial fibrillation and other arrhythmias treatment is at the domestic leading level. Moreover, transesophageal atrial pacing for diagnosis of supraventricular atthythmias and examination for sinus node and atrioventricular node function, which is now widely used in the whole country, was firstly introduced by Prof. Zaiying Lu in the country. Our genetic diagnosis of arrhythmias is at leading domestic level and is in open service.

3.We are in domestic as well as international advanced level in molecular diagnosis and genotyping for individualized therapy – translational medicine area. We have performed gene sequencing of CYP2C9, VKORC1 and CYP4F2 polymorphisms to guide clinical dose determination of warfarin; CYP2C19 polymorphism to predict clopidogrel resistance, guiding the anti-platelet drug uses for patients with acute coronary syndrome, especially for those receiving coronary stent implantation; genetic diagnosis of genetic diseases; gene mutation detection to predict sudden death.

4.For the diagnosis and treatment of hypertension, we are also at domestic leading level. We arrange 2 to 4 public education of hypertension prevention and treatment at hypertension day annually in Wuhan. We have also achieved great success in the etiological diagnosis of refractory hypertension, and have firstly established new screening techniques of primary aldosteronism (Chinese Journal of Cardiovascular diseases 2006;34(10): 873-876), which could significantly improve the diagnosis level. Furthermore, we have adopted genetic diagnosis technique for the diagnosis of genetic single-gene hereditary hypertension, and carried out genetic polymorphism detection for the treatment guidance of refractory hypertension.

5.In fields of diagnosis and treatment of heart failure / cardiomyopathy, we are in the domestic first-class level. We have used NT-proBNP routinely to guide clinical diagnosis and observe the treatment efficacy; ventilator treatment for critically ill patients, some using phlebotomy, dialysis, and IABP therapies and have achieved very good results; for patients with severe myocarditis complicated with heart failure and pump failure, and liver and renal dysfunction, we use IABP, ventilation, dialysis, and medication therapy after multidisciplinary consultation, and many have been fully recovered. We have also carried out interventional therapy for valvular diseases, molecular diagnosis and risk prediction for cardiomyopathy, which is at international advanced level.

Academic status

Department of Cardiology of Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology has received great attentions and supports from the nation. After been established in 1959, Department of cardiology has been approved as a master's degree discipline in 1979, doctoral degree discipline in 1981, and the key disciplines in Hubei Province in 1996 Meanwhile, the Institute of Hypertension was established in 1998. The department has also been authorized the key disciplines of Ministry of Education in 2001, the National Clinical Test Center in 2006, and the national key clinical department of Ministry of Health in 2011. Member of Chinese Society of Cardiology, vice president of Chinese Association of Cardiology in Hubei and Wuhan Association of Cardiology is in our discipline. We are in domestic leading in teaching, health care, research, personnel training, and other aspects of comprehensive strength.

Our department is not only the first department to conduct thrombolytic therapy for acute myocardial infarction, but also the one of first to carry out coronary angiography and coronary angioplasty, pacemaker implantation, catheter ablation for arrhythmia, and stent implantation for aortic disease. We have gained a wealth of experience and provided services in Hubei and surrounding provinces.

In addition, our basic research in cardiovascular disease is also at the domestic leading level, especially in diagnosis and treatment of secondary hypertension, molecular diagnosis, and genotyping for clinical individualized therapy fields.

Research achievement

Since 2000, the Department of cardiology has already won 51 national projects for a total nearly 20 million funding, including 34 National Natural Science Foundation of China (NSFC) projects (including two key projects of the NSFC), three 863 projects, three 973 projects, one international cooperation project, and one key project of clinical discipline of Ministry of Health subordinates. According to incomplete statistics, our staffs have published approximately 700 articles as the first authors or the corresponding authors, of which are mainly national core journals or source journals. Besides, we also published over 90 articles in SCI journals, including papers in Circ Res, Hypertension, Cancer Res, J Pharmacol Exper Ther, Mol Cancer Ther, Am J Physiol Heart Circ Physiol, Circ Cardiovasc Genetics, Gene Ther, and Hum Gene Ther, etc., with the highest impact factor of nearly 15. We have also applied for 10 national patents, which was approved four, and six remaining in open real trials. Moreover, we have also gained one first prize of Natural Science Award of Ministry of Education, one first prize of Hubei Science and Technology Progress Award, three second prizes of Hubei Science and Technology Progress Award, three second prizes of Wuhan Science and Technology Progress Award, and two third prizes of Wuhan Science and Technology Progress Award.

International cooperation

Our department of cardiology is often associated with foreign experts in the field to maintain academic links. We invite 3 to 4 foreign experts and professors in related fields to our hospital for academic exchange annually, to bring us the latest and most cutting-edge international progress. Besides, we send about 2 to 3 young doctors and nurses to famous hospitals and research institutions abroad per year for training or postdoctoral work, to learn the newest and most advanced management and clinical experience. We are also regularly invited to participate in renowned international academic conferences as well, to bring back the latest knowledge in the cardiovascular field.

As a national subordinate hospital department, Department of Cardiology of Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology has received great attentions and supports from the nation. After been established in 1959, Department of cardiology has been approved as a master's degree discipline in 1979, doctoral degree discipline in 1981, and the key disciplines in Hubei Province in 1996 Meanwhile, the Institute of Hypertension was established in 1998. The department has also been authorized the key disciplines of Ministry of Education in 2001, the National Clinical Test Center in 2006, and the national key clinical department of Ministry of Health in 2011.

Currently, the department has in total 101 employees, including 10 health workers (heart function rooms and laboratories), 54 nurses, 1 secretary, and 36 specialists with advanced medical technologies and concepts. We have 26 doctors with doctorate, seven with mastership, and three with Bachelor degree. Among thm, there are 17 Senior title, and 12 Middle title, including 11 doctoral supervisors. At present, Professor Daowen Wang is the Director of Internal Medicine and the Department of Cardiology, Professor Lin Wang is the Deputy Director of the Department of Cardiology, Professor Hesong Zeng is the Chief of the cardiac catheterization laboratory. Professor Daowen Wang also serves as the Director of Institute of Hypertension.

Our department comprises five parts, three wards with 110 beds (including 10 beds in CCU), cardiac catheterization room, hybrid operating room, cardiac function examination center (including echocardiography), and the Institute of Hypertension (including Gene Therapy Center and genetic laboratory platform).

We especially focus on the difficult cases and mainly provide services for acute and critically ill patients. While conducting routine clinical diagnosis and treatment of cardiovascular diseases (such as interventional therapies for coronary heart disease and rheumatic heart disease, radiofrequency ablation for arrhythmia, etc.), we also carry out diagnosis and stent implantation for treatment of aortic dissection (including acute and subacute phases), screening and treatment of primary aldosteronism, genetic diagnosis for treatment guidance and individualized therapy as well.

As the forefront of the domestic cardiovascular medicine in general hospital, there are 60,000 outpatient visits, 3,000 people treated annually in recent years, including nearly 50% outsider patients. The success rate of emergency treatment of acute myocardial infarction is more than 90%.

We dedicate to provide high quality comprehensive healthcare for the patients, and make every effort to forge ahead. Our good ethics and high-quality medical and research level have received high degree of recognition and praise from both domestic and international communities.